Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development
October 10 2023 - 7:00AM
Neumora Therapeutics, Inc. (Nasdaq: NMRA), a
clinical-stage biopharmaceutical company redefining neuroscience
drug development, today announced the appointment of Robert Lenz,
M.D., Ph.D., as executive vice president, head of research and
development. Dr. Lenz is a member of Neumora’s Executive Team
reporting to Henry Gosebruch, chief executive officer.
“I am delighted to welcome Rob to the Neumora team. His deep
domain expertise in neuroscience combined with his vast experience
executing successful clinical trials to develop first-in-class
medicines will be invaluable as we advance our innovative pipeline
including our recently initiated Phase 3 KOASTAL program for
navacaprant in MDD,” said Henry Gosebruch, chief executive officer
of Neumora. “With Rob’s R&D leadership and our strong team,
capabilities and programs, I believe we are on the precipice of
pioneering a new era of medicines in brain disorders and making a
difference for patients.”
Dr. Lenz brings 20 years of experience developing novel drugs in
areas of significant unmet medical need and vast clinical execution
expertise to Neumora. In his most recent role as head of global
development at Amgen, Dr. Lenz oversaw more than 130 interventional
study starts with more than 53,000 patients enrolled in over 50
countries. Additionally, Dr. Lenz played a key role in the
development and approval of multiple medicines including TEZSPIRE®,
the first anti-TSLP antibody for severe asthma; AIMOVIG®, the first
specific preventative therapy for migraine; and DUOPA®, a
combination of carbidopa (an aromatic amino acid decarboxylation
inhibitor) and levodopa (an aromatic amino acid) for motor
fluctuations in advanced Parkinson’s disease1.
“I am excited to join Neumora’s strong team of R&D leaders,
and to leverage my expertise to advance our industry-leading
pipeline of novel neuropsychiatry and neurodegeneration programs,”
said Dr. Robert Lenz, executive vice president, head of research
and development, Neumora. “I have closely followed Neumora since
its beginnings, and I’ve been impressed with the quality of
programs the Company has assembled, each with a novel mechanism of
action, and the data generated. I believe that we have several
product candidates that have the potential to make a difference for
patients living with brain disorders.”
About Robert Lenz, M.D., Ph.D., executive vice
president, head of research and developmentDr. Rob Lenz is
executive vice president, head of research and development at
Neumora. In this role, Dr. Lenz will lead the Company’s research,
clinical and regulatory efforts, leveraging his 20 years of
neuroscience drug development expertise.
Prior to Neumora, Dr. Lenz was senior vice president, head of
global development, at Amgen. Dr. Lenz joined Amgen in 2012 as the
global development lead for the company’s neuroscience programs.
During his time with the company, he assumed positions of greater
responsibility, ultimately serving as the therapeutic area head and
vice president of inflammation, nephrology, and neuroscience
development and the head for the Center for Design & Analysis,
where he was instrumental in the broad adoption of innovative trial
designs across Amgen’s portfolio.
Prior to joining Amgen, Dr. Lenz spent over eight years at
Abbott within clinical development, ultimately serving as vice
president and head of the neurology, psychiatry and anesthesiology
therapeutic area.
Dr. Lenz received his M.D., Ph.D. with honors from the
University of Maryland, with a research focus inNeuropharmacology.
He completed his residency in Neurology at UCLA.
About NeumoraNeumora Therapeutics, Inc. is a
clinical-stage biopharmaceutical company founded to confront the
global brain disease crisis by taking a fundamentally different
approach to the way treatments for brain diseases are developed.
Neumora’s therapeutic pipeline currently consists of seven clinical
and preclinical neuroscience programs that target novel mechanisms
of action for a broad range of underserved neuropsychiatric
disorders and neurodegenerative diseases. Neumora’s work is
supported by an integrated suite of translational, clinical, and
computational tools to generate insights that can enable precision
medicine approaches. Neumora’s mission is to redefine neuroscience
drug development by bringing forward the next generation of novel
therapies that offer improved treatment outcomes and quality of
life for patients suffering from brain diseases.
Neumora has operations in the Greater Boston Area and South San
Francisco. For additional information, please visit
www.neumoratx.com and follow us on Twitter: @NeumoraTx.
Investors:
Helen Rubinstein
(315)
382-3979 Helen.Rubinstein@neumoratx.com
Media:Katie EnglemanKatie@1abmedia.com
_________________________________1 The following are trademarks
of the respective companies listed: TEZSPIRE®, AIMOVIG® – Amgen;
DUOPA® – AbbVie.
Neumora Therapeutics (NASDAQ:NMRA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Neumora Therapeutics (NASDAQ:NMRA)
Historical Stock Chart
From Sep 2023 to Sep 2024